EQT Life Sciences portfolio company Endotronix acquired by Edwards Lifesciences

EQT Life Sciences was the lead investor in Endotronix’s series D Financing, investing from its LSP Health Economics Fund 2. Endotronix is a leader in heart failure management solutions. In June 2024 it received approval for Cordella, an implantable pulmonary artery pressure sensor that allows for early, targeted therapeutic intervention. On August 19 th , the acquisition was approved by the regulatory authorities in the US.

Find the pre-regulatory approval press release here.

EQT Life Sciences was formed in 2022 following the integration of LSP, a leading European life sciences venture capital firm, into the EQT platform. As LSP, the firm raised over EUR 3.0 billion (USD 3.5 billion) and supported the growth of more than 150 companies since it started to invest over 30 years ago. With a dedicated team of highly experienced investment professionals coming from backgrounds in medicine, science, business, and finance, EQT Life Sciences backs entrepreneurs who have ideas that could truly make a difference for patients.

The team combines deep sector knowledge, analytical skills and investment experience to provide the added value that inventors seek. EQT Life Sciences’ broad life sciences and healthcare network is highly complementary to EQT’s global healthcare sector franchise and makes EQT an even better and more innovative healthcare investor.

For more information, go to www.eqtgroup.com/private capital/life-sciences/